![]() |
市場調査レポート
商品コード
1374810
カバー付きステントの世界市場-2023年~2030年Global Covered Stents Market -2023-2030 |
||||||
カスタマイズ可能
適宜更新あり
|
カバー付きステントの世界市場-2023年~2030年 |
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
|
被覆ステントは血管ステントの一種であり、布製のコーティングによりチューブを形成するが、むき出しの金属ステントのように拡張可能です。カバードステントは血管内動脈瘤修復術などの血管内外科手術に使用されます。被覆ステントは、ポリテトラフルオロエチレン(PTFE)などの布またはグラフト材料で金属ステントを被覆したものです。末梢動脈疾患管理におけるさまざまな臨床応用があります。
動脈硬化性疾患の治療、異所性血管穿孔や破裂の封鎖、動脈瘤や偽動脈瘤の排除、動静脈瘻の治療、不全透析グラフトの管理などの用途があります。カバードステントは、先天性心臓インターベンションの際に、狭窄または損傷した血管の治療や、不要な血管の接続を排除するために使用されます。
カバードステントはまた、生来の冠動脈の血栓の多い病変にも使用されます。カバードステントは、血管穿孔の効果的な救済策を提供し、冠動脈瘤の排除のための手術に代わるものであり、壊れやすい塞栓しやすいプラークの治療において潜在的な役割を担っています。
カバードステントは主に、生命を脅かす可能性のある冠動脈穿孔や冠動脈瘤の治療に使用されてきました。先行研究によると、カバードステントの使用は無イベント生存率を向上させ、緊急手術を行わずに生命を脅かす状況を管理することを可能にし、死亡率、心タンポナーデ、主要有害心イベントの発生率を有意に低下させることが示唆されています。
冠動脈疾患は、心臓に血液を供給する動脈(冠動脈と呼ばれる)の壁にプラークが蓄積することによって引き起こされます。プラークはコレステロールの沈着でできています。プラークが蓄積すると、時間の経過とともに動脈の内側が狭くなります。この過程はアテローム性動脈硬化と呼ばれます。
例えば、疾病管理予防センターが更新したファクトシート2023によると、冠動脈性心疾患は最も一般的な心臓病のタイプであり、2021年には375,476人が死亡しました。2021年には、CADによる死亡者の約10人に2人が65歳未満の成人です。
さらに、被覆型ステントの技術的進歩、高齢者人口の増加、冠動脈疾患の有病率の増加、ステント留置による患者の転帰の改善などが挙げられます。薬剤溶出ステント(DES)技術の進歩は、ステントデリバリーを改善し、より生体適合性の高い薬剤ポリマーを開発するために、既存のプラットフォームを継続的に改良することから成っています。
カバー付きステントの最も一般的な故障メカニズムは、デリバリーの失敗、ステントの脱落、穿孔の封鎖の失敗です。送達の失敗はグラフトマスターで多く、ステントの脱落はPKパピルスで多いです。送達能を最適化し、合併症のリスクを最小化するためには、カバードステントのデザインにさらなる改良が必要です。
また、このような特殊な医療機器には高いコストがかかります。カバードステントは従来のステントよりも高価であることが多く、特にヘルスケア予算に制約のある地域では、その導入が制限される可能性があります。さらに、カバードステントの配備に熟練したインターベンショナル・カーディオロジストの数が限られていることも、市場全体の妨げとなっています。
Covered stent is a type of vascular stent with a fabric coating that creates a contained tube but is expandable like a bare metal stent. Covered stents are used in endovascular surgical procedures such as endovascular aneurysm repair. Covered stents are composed of fabric or graft material, such as polytetrafluoroethylene (PTFE), covering a metal stent. They have various clinical applications in peripheral arterial disease management.
Applications include treatment of atherosclerotic disease, sealing iatrogenic vessel perforations or ruptures, exclusion of aneurysms and pseudoaneurysms, treatment of arteriovenous fistulae, and management of failing dialysis grafts. Covered stents are used during congenital cardiac interventions to treat stenotic or injured vessels or to exclude unwanted vascular connections.
Covered stents were also utilised in thrombus-laden lesions in native coronary arteries. Covered stents offer an effective bail-out strategy in vessel perforations, are an alternative to surgery for the exclusion of coronary aneurysms, and have a potential role in the treatment of friable embolisation-prone plaques.
Covered stents have been mainly used for the treatment of potentially life-threatening coronary artery perforation and coronary artery aneurysms. Prior studies suggest that the use of covered stents improves event-free survival, enabling a life-threatening situation to be managed without emergency surgery and with significantly reduced rates of mortality, cardiac tamponade, and major adverse cardiac events
Coronary artery disease is caused by plaque buildup in the wall of the arteries that supply blood to the heart (called coronary arteries). Plaque is made up of cholesterol deposits. Plaque buildup causes the inside of the arteries to narrow over time. This process is called atherosclerosis
For instance, according to the Centers for Disease Control and Prevention updated factsheet 2023, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. About 1 in 20 adults age 20 and older have CAD (about 5%).2 In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old.
Furthermore, technological advancements in covered stents, the rise in the prevalence of the geriatric population, the increase in the prevalence of coronary artery diseases and improvement in patient outcomes with stenting. Advancements in drug-eluting stent (DES) technologies have consisted of continually refining existing platforms to improve stent delivery and develop more biocompatible drug polymers.
The most common failure mechanisms of covered stents are failure of delivery, stent dislodgement, and failure to seal the perforation. Failure of delivery was more common with Graftmaster, while stent dislodgement was more common with PK Papyrus. Further improvements in covered stent design are needed to optimize deliverability and minimize the risk of complications.
Also, the high cost associated with these specialized medical devices. Covered stents are often more expensive than traditional stents, which can limit their adoption, particularly in regions with constrained healthcare budgets. Moreover, the limited availability of skilled interventional cardiologists proficient in deploying covered stents further hampers the overall market.
The global covered stents is segmented based on product type, material type, application, end-user and region.
The balloon expandable vascular covered stent from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Balloon Expandable Vascular Covered Stent is indicated for the treatment of atherosclerotic lesions in common and external iliac arteries. Balloon-expandable covered stents are medical devices used in interventional cardiology and vascular surgery to treat vascular conditions like aneurysms and stenoses. They consist of a metal framework covered with a synthetic fabric or polymer material.
Moreover, in September 2022, Medtronic set forth that it recently received a CE mark for its Radiant balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the Endurant II/Iis stent graft system. The Endurant II/Iis stent graft and Radiant covered stent offer a standardized, fully on-label, off-the-shelf solution for short-neck, juxtarenal abdominal aortic aneurysms (AAA). This enables safe and effective endovascular repair in both urgent and elective juxtarenal AAA cases, with a proven device combination, backed by clinical outcomes.
Europe is estimated to hold about 28.4% of the total market share throughout the forecast period, owing to the novel product launches, technological advancements, collaboration with the key players, approvals and others that will drive this region further during the forecast period.
For instance, in September 2022, Getinge joined forces with Medtronic to launch a Radiant stent for ChEVAR procedures in Europe which received a CE mark.
Radiant, is the first covered stent which is designed for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/Iis stent graft system. It maintains perfusion to renal arteries when used in combination with the stent graft
Furthermore, in May 2021, iVascular has recently received CE mark approval for its BX-covered stent iCover. Balloon-expanding (BX) covered stents are commonly used for treating arteriosclerotic lesions in renal and iliac arteries and for the treatment of aneurysms and ruptures.
COVID-19 had a substantial impact on the global covered stents market importantly, new studies and registers shows that the percentage of stent thrombosis increased during the COVID-19 pandemic, even up to 8.1-21%, however, the study populations were relatively low. COVID-19, due to direct and indirect effects, creates a significant burden on the cardiovascular system.
Due to the high infection rate and lockdown regulations brought on by the COVID-19 pandemic, surgical procedures have been affected. Additionally, patients with cardiovascular diseases have experienced delays in diagnosis and treatment as a result of fewer people visiting hospitals and diagnostic facilities, which has affected the covered stent market.
The major global players in the covered stents market include: Becton, Dickinson and Company, B. Braun Interventional Systems Inc., Getinge, Insrtumed Surgical, Inc., Boston Scientific Corporation, Biotronik, Mermaid Medical, Gore Medical, Getz Healthcare, iVascular S.L.U and among others.
The global covered stents market report would provide approximately 69 tables, 70 figures, and 185 Pages.
LIST NOT EXHAUSTIVE